CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 13 enrolled
Drug / intervention
NeuroStar® TMS device (Neuronetics, Atlanta, GA)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02939560
NCT02939560N/ACompleted
CompareCT.gov

Transcranial Magnetic Stimulation for Adults With Autism Spectrum Disorder and Depression

Medical University of South Carolina·interventional·Posted Oct 20, 2016·Updated Oct 1, 2019

In Brief

A clinical study evaluating NeuroStar® TMS device (Neuronetics, Atlanta, GA) for Autism Spectrum Disorder and 3 related conditions. Completed, enrolled 13 participants across 1 site.

Detailed Summary

The goal of this proposal is to investigate whether a standard rTMS protocol for depression, including multiple sessions applied to left dorsolateral prefrontal cortex (DLPFC) results in reduction of depressive symptoms for adult patients with ASD and MDD (Aim 1). The secondary goal is to investigate and whether there is any beneficial reduction in the core symptoms of autism (Aim 2).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism Spectrum Disorder, Depression, Depressive Disorder, Major Depressive Disorder
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedOct 20, 2016
Enrollment StartSep 1, 2016
Primary CompletionJun 1, 2018
Study CompletionSep 20, 2018
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 9.7 years ago

Interventions

NeuroStar® TMS device (Neuronetics, Atlanta, GA)device

Participants in this study arm will be evaluated before and after receiving rTMS. Outcome measures will include social skills rating scales, depression rating scales and cognitive tasks while undergoing functional magnetic resonance imaging (fMRI).